What is Moxifloxacine EG?
Moxifloxacine EG injection is used to treat bacterial infections in many different parts of the body.
Moxifloxacine EG belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, Moxifloxacine EG will not work for colds, flu, or other virus infections.
Moxifloxacine EG is to be given only by or under the direct supervision of your doctor.
Moxifloxacine EG indications
Community Acquired Pneumonia
Moxifloxacine EG is indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumonia .
MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.
Uncomplicated Skin And Skin Structure Infections
Moxifloxacine EG is indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.
Complicated Skin And Skin Structure Infections
Moxifloxacine EG is indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.
Complicated Intra-Abdominal Infections
Moxifloxacine EG is indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species.
Plague
Moxifloxacine EG is indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of Moxifloxacine EG could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.
Acute Bacterial Sinusitis
Moxifloxacine EG is indicated in adult patients (18 years of age and older) for the treatment of acute bacterial sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
Because fluoroquinolones, including Moxifloxacine EG, have been associated with serious adverse reactions and for some patients ABS is self-limiting, reserve Moxifloxacine EG for treatment of ABS in patients who have no alternative treatment options.
Acute Bacterial Exacerbation Of Chronic Bronchitis
Moxifloxacine EG is indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis.
Because fluoroquinolones, including Moxifloxacine EG, have been associated with serious adverse reactions and for some patients ABECB is self-limiting, reserve Moxifloxacine EG for treatment of ABECB in patients who have no alternative treatment options.
Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacine EG and other antibacterial drugs, Moxifloxacine EG should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Moxifloxacine EG?
Use Moxifloxacine EG tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Moxifloxacine EG tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Moxifloxacine EG tablets refilled.
- Take Moxifloxacine EG tablets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Drink plenty of liquids while taking Moxifloxacine EG tablets.
- Do not take a product that has magnesium, aluminum, calcium, zinc, iron, or sucralfate in it within 8 hours before or 4 hours after you take Moxifloxacine EG tablets. Examples of these products include antacids, multivitamins, chewable/buffered didanosine, didanosine suspension, and quinapril. Check with your doctor or pharmacist if you have a question about whether you should separate Moxifloxacine EG tablets from a certain food or product.
- Take Moxifloxacine EG tablets on a regular schedule to get the most benefit from it.
- To clear up your infection completely, take Moxifloxacine EG tablets for the full course of treatment. Keep taking it even if you feel better in a few days.
- If you miss a dose of Moxifloxacine EG tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take more than 1 dose in the same day.
Ask your health care provider any questions you may have about how to use Moxifloxacine EG tablets.
Uses of Moxifloxacine EG in details
Use: Labeled Indications
Treatment of mild to moderate community-acquired pneumonia, including multidrug-resistant Streptococcus pneumoniae (MDRSP); acute bacterial exacerbation of chronic bronchitis; acute bacterial rhinosinusitis; complicated and uncomplicated skin and skin structure infections; complicated intra-abdominal infections; prophylaxis and treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis.
Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve Moxifloxacine EG for use in patients who have no alternative treatment options for acute exacerbation of chronic bronchitis or acute sinusitis.
Off Label Uses
Anthrax
Based on the Centers for Disease Control and Prevention (CDC) Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults, Moxifloxacine EG is as an effective and recommended agent for the treatment of cutaneous anthrax and an alternative agent for postexposure prophylaxis and treatment of systemic anthrax (with or without possible/confirmed meningitis).
Bite wounds (animal/human)
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTI), Moxifloxacine EG is an effective and recommended alternative option for treatment of bite wounds, particularly in patients with a human bite wound who are hypersensitive to beta-lactams.
Diabetic foot infections
Based on the Infectious Diseases Society of America (IDSA) guidelines for diagnosis and treatment of diabetic foot infections, Moxifloxacine EG is an effective and recommended treatment option for moderate to severe diabetic foot infections.
Meningitis, bacterial
Based on the Infectious Diseases Society of America (IDSA) guidelines for the management of bacterial meningitis and health care-associated ventriculitis and meningitis, Moxifloxacine EG is an effective and recommended alternative agent for the treatment of meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.
Mycoplasma genitalium
Noncontrolled trials support the use of Moxifloxacine EG as alternative treatment in patients with persistent detection of Mycoplasma genitalium who have not responded to or are intolerant of azithromycin. Additional data may be necessary to further define the role of Moxifloxacine EG in this condition.
Pelvic inflammatory disease
Based on the Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, Moxifloxacine EG may be considered as alternative treatment in patients allergic to cephalosporins with pelvic inflammatory disease. The CDC recommends use as an alternative therapy only if standard parenteral cephalosporin therapy is not feasible and community prevalence of quinolone-resistant gonococcal organisms is low. Culture sensitivity must be confirmed.
Surgical prophylaxis
Based on the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Surgical Infection Society (SIS), and the Society of Healthcare Epidemiology of America (SHEA) guidelines for antimicrobial prophylaxis in surgery, Moxifloxacine EG (systemic) may be administered (in combination with either clindamycin or vancomycin) as an alternative regimen in patients with beta-lactam allergy.
Tuberculosis (second-line therapy)
Based on the American Thoracic Society, Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) Treatment of Tuberculosis guidelines, Moxifloxacine EG (systemic) given for second-line therapy of tuberculosis is effective and recommended in the management of this condition.
Moxifloxacine EG description
Each tablet contains Moxifloxacin HCl 436.8 mg equivalent to Moxifloxacine EG 400 mg. It also contains croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, hypromellose, macrogol 4000, titanium dioxide (E171) and ferric oxide (E172) as inactive constituents.
Each 250 mL solution for infusion contain Moxifloxacine EG HCl 436.8 mg equivalent to Moxifloxacine EG 400 mg. It also contains sodium chloride, 1N hydrochloric acid, 2N sodium hydroxide and water for injection. The solution for infusion (250 mL) contains sodium 34 mmol.
Moxifloxacine EG dosage
Moxifloxacine EG Dosage
Generic name: Moxifloxacine EG HYDROCHLORIDE 5mg in 1mL
Dosage form: ophthalmic solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Instill one drop in the affected eye 3 times a day for 7 days.
More about Moxifloxacine EG (Moxifloxacine EG ophthalmic)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Support Group
- Pricing & Coupons
- En Espanol
- 12 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Moxifloxacine EG
- Moxifloxacine EG drops
- Moxifloxacine EG (Advanced Reading)
- Other brands: Moxeza
Professional resources
- Moxifloxacine EG eent (AHFS Monograph)
- Moxifloxacine EG (FDA)
Related treatment guides
- Conjunctivitis, Bacterial
Ophthalmic Surgery
Moxifloxacine EG interactions
See also:
What other drugs will affect Moxifloxacine EG?
Tablet: For the following substances, absence of a clinically relevant interaction with Moxifloxacine EG was proven: Atenolol, ranitidine, calcium supplements, theophylline, oral contraceptives, glibenclamide, itraconazole, digoxin, morphine, probenecid. No dose adjustment is necessary for these drugs.
Antacids, Minerals and Multivitamins: Concomitant ingestion of Moxifloxacine EG with antacids, minerals and multivitamins may result in impaired absorption of Moxifloxacine EG after oral administration due to formation of chelate complexes with the multivalent cations contained in these preparations. This may lead to plasma concentrations considerably lower than desired. Hence, antacids, antiretroviral drugs (eg, didanosine) and other preparations containing magnesium or aluminium, sucralfate and agents containing iron or zinc should be administered at least 4 hours before or 2 hours after ingestion of an oral Moxifloxacine EG dose.
Ranitidine: The concomitant administration with ranitidine did not change the absorption characteristics of Moxifloxacine EG. Absorption parameters (Cmax, tmax, AUC) were comparable, indicating absence of an influence of gastric pH on Moxifloxacine EG uptake from the gastrointestinal tract.
Calcium Supplements: When given with high dose calcium supplements, only a slightly reduced rate of absorption was observed, while extent of absorption remained unaffected. The effect of high-dose calcium supplements on the absorption of Moxifloxacine EG is considered as clinically not relevant.
Theophylline: In accordance with in vitro data, no influence of Moxifloxacine EG on theophylline pharmacokinetics (and vice versa) at steady state was detected in humans, indicating that Moxifloxacine EG does not interfere with the 1A2 subtypes of the CYP450 enzymes.
Warfarin: No interaction during concomitant treatment with warfarin on pharmacokinetics, prothrombin time and other coagulation parameters has been observed.
Changes in International Normalized Ratio (INR): Cases of increased anticoagulant activity have been reported in patients receiving anticoagulants concurrently with antibiotics, including Moxifloxacine EG. The infectious disease (and its accompanying inflammatory process), age and general status of the patient are risk factors. Although an interaction between Moxifloxacine EG and warfarin was not demonstrated in clinical trials, INR monitoring should be performed and, if necessary, the oral anticoagulant dosage should be adjusted as appropriate.
Oral Contraceptives:
No interaction has occured following concomitant oral administration of Moxifloxacine EG with oral contraceptives.Antidiabetics: No clinically relevant interaction was seen between glibenclamide and Moxifloxacine EG.
Itraconazole: Exposure (AUC) to itraconazole was only marginally altered under concomitant Moxifloxacine EG treatment. Pharmacokinetics of Moxifloxacine EG were not significantly altered by itraconazole. No dose adjustment is necessary for itraconazole when given with Moxifloxacine EG and vice versa.
Digoxin: The pharmacokinetics of digoxin are not significantly influenced by Moxifloxacine EG (and vice versa). After repeated dosing in healthy volunteers, Moxifloxacine EG increased Cmax of digoxin by approximately 30% at steady state without affecting AUC or trough levels.
Morphine:
Parenteral administration of morphine with Moxifloxacine EG did not reduce the oral bioavailability of Moxifloxacine EG and only slighlty decreased Cmax (17 %).
Atenolol: The pharmacokinetics of atenolol are not significantly altered by Moxifloxacine EG. Following single dose administration in healthy subjects, AUC was marginally increased (by approximately 4%) and peak concentrations were decreased by 10%.
Probenecid: No significant effect on apparent total body clearance and renal clearance of Moxifloxacine EG was found in a clinical study investigating the impact of probenecid on renal excretion.
Charcoal: Concomitant dosing of charcoal and oral Moxifloxacine EG 400 mg reduced the systemic availability of the drug by >80% by preventing absorption in vivo. The application of activated charcoal in the early absorption phase prevents further increase of systemic exposure in cases of overdose.
After IV drug administration, carbo medicinalis only slightly reduces systemic exposure (approximately 20%).
Food and Dairy Products: Absorption of Moxifloxacine EG was not altered by food intake (including dairy products). Moxifloxacine EG can be taken independent from food intake.
Infusion: No interaction during concomitant treatment with warfarin, itraconazole, theophylline, digoxin and oral contraceptives.
Moxifloxacine EG side effects
See also:
What are the possible side effects of Moxifloxacine EG?
Applies to Moxifloxacine EG ophthalmic: ophthalmic solution
As well as its needed effects, Moxifloxacine EG ophthalmic (the active ingredient contained in Moxifloxacine EG) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking Moxifloxacine EG ophthalmic, check with your doctor immediately:
Incidence not known:
- Fainting or loss of consciousness
- fast or irregular breathing
- itching
- skin rash
- swelling of the eyes or eyelids
- tightness in the chest or wheezing
- trouble with breathing
Minor Side Effects
Some Moxifloxacine EG ophthalmic side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
More common:
- Burning, dry, or itching eyes
- change in vision
- decreased vision
- dry eye
- excessive tearing
- eye discharge
- itching of the eye
- pain in the eye
- red, sore eyes
- redness of the eye
- swelling of the eye, eyelid, or inner lining of the eyelid
- tearing
- Body aches or pain
- congestion
- cough or hoarseness
- decreased hearing
- dryness or soreness of the throat
- fever or chills
- general body discomfort
- lower back or side pain
- painful or difficult urination
- rash
- rubbing or pulling of the ears (in children)
- runny nose
- sore throat
- tender, swollen glands in the neck
- trouble with swallowing
- voice changes
- vomiting and diarrhea (in infants)
Moxifloxacine EG contraindications
See also:
What is the most important information I should know about Moxifloxacine EG?
You should not use this medication if you have a history of myasthenia gravis, or if you are allergic to Moxifloxacine EG or similar antibiotics such as ciprofloxacin (Cipro), gemifloxacin (Factive), levofloxacin (Levaquin), ofloxacin (Floxin), norfloxacin (Noroxin), and others.
Before taking Moxifloxacine EG, tell your doctor if you have a heart rhythm disorder, kidney or liver disease, joint problems, a history of seizures, low levels of potassium in your blood (hypokalemia), muscle weakness or trouble breathing, a personal or family history of Long QT syndrome, or if you have ever had an allergic reaction to an antibiotic.
Avoid taking antacids, vitamin or mineral supplements, sucralfate (Carafate), or didanosine (Videx) powder or chewable tablets within 8 hours before or 4 hours after you take Moxifloxacine EG. These other medicines can make Moxifloxacine EG much less effective when taken at the same time.
Taking Moxifloxacine EG can make your skin more sensitive to sunlight. Avoid exposure to sunlight, sun lamps, or tanning beds.
Moxifloxacine EG may cause swelling or tearing of a tendon (the fiber that connects bones to muscles in the body), especially in the Achilles' tendon of the heel. These effects may be more likely to occur if you are over 60, if you take steroid medication, or if you have had a kidney, heart, or lung transplant. Stop taking Moxifloxacine EG and call your doctor at once if you have sudden pain, swelling, tenderness, stiffness, or movement problems in any of your joints. Rest the joint until you receive medical care or instructions.
Do not share this medication with another person (especially a child), even if they have the same symptoms you do.
Active ingredient matches for Moxifloxacine EG:
Moxifloxacin in Belgium, France.
List of Moxifloxacine EG substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Moxifloxacine VIOSER (Netherlands) | |
| Moxifloxacino Actavis (Spain) | |
| Moxifloxacino Apotex (Spain) | |
| Moxifloxacino Aurobindo (Spain) | |
| Moxifloxacino Bayfarma (Spain) | |
| Moxifloxacino Cinfa (Spain) | |
| Moxifloxacino G.E.S. (Spain) | |
| Moxifloxacino Hetero (Spain) | |
| Moxifloxacino Kabi (Spain) | |
| Moxifloxacino Kern Pharma (Spain) | |
| Moxifloxacino Krka (Spain) | |
| Moxifloxacino MK (Colombia) | |
| Moxifloxacino Mylan (Spain) | |
| Moxifloxacino Pharmathen (Spain) | |
| Moxifloxacino Qualigen (Spain) | |
| Moxifloxacino Ratiopharm (Spain) | |
| Moxifloxacino Sandoz (Spain) | |
| Moxifloxacino Stada (Spain) | |
| Moxifloxacino Tevagen (Spain) | |
| Moxifloxacino Zentiva (Spain) | |
| Moxifloxan (Bulgaria) | |
| Moxifor (Turkey) | |
| Moxiforce (South Korea) | |
| MOXIFORD | |
| MOXIFORD EYE DROP 1 packet / 5 ML eye drop each (Leeford Healthcare Ltd) | $ 0.80 |
| Moxiford 400mg Tablet (Leeford Healthcare Ltd) | $ 0.47 |
| Moxifresh | |
| Moxifresh NA Eye Drop (Smart Laboratories Pvt Ltd) | $ 0.23 |
| Moxifur (Russian Federation) | |
| MOXIGEN | |
| MOXIGEN EYE DROP 1 packet / 5 ML eye drop each (Renova Life sciences Pvt Ltd) | $ 0.86 |
| Moxigen 0.5% w/v Eye Drop (Renova Life sciences Pvt Ltd) | $ 0.86 |
| Moxigene (Pakistan) | |
| Moxiget (Georgia) | |
| MOXIGOOD | |
| MOXIGOOD 400 MG TABLET 1 strip / 5 tablets each (Cadila Pharmaceuticals Ltd) | $ 1.33 |
| Moxigood 400mg Tablet (Cadila Pharmaceuticals Ltd) | $ 0.27 |
| Moxigood 400mg Injection (Cadila Pharmaceuticals Ltd) | $ 0.02 |
| Moxigram (Bangladesh, India) | |
| Moxigram 0.5% EYE-DPS / 5ml (Micro Vision) | $ 0.88 |
| 0.5 % x 5ml (Micro Vision) | $ 0.88 |
| MOXIGRAM 400 MG TABLET 1 strip / 5 tablets each (Micro Vision) | $ 1.40 |
| MOXIGRAM D EYE DROP 1 packet / 10 ML eye drop each (Micro Vision) | $ 1.30 |
| MOXIGRAM EYE DROP 1 packet / 5 ML eye drop each (Micro Vision) | $ 1.30 |
| MOXIGRAM EYE OINTMENT 1 tube / 5 GM eye ointment each (Micro Vision) | $ 0.59 |
| MOXIGRAM INFUSION 1 bottle / 100 ML infusion each (Micro Vision) | $ 1.45 |
| MOXIGRAM eye drops 0.5 % x 5ml (Micro Vision) | $ 0.88 |
See 879 substitutes for Moxifloxacine EG | |
References
- PubChem. "moxifloxacin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "moxifloxacin". http://www.drugbank.ca/drugs/DB00218 (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Moxifloxacine EG are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Moxifloxacine EG. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
